A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

• Status: Completed
• Trial end date: 2006-09-15
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the trial was to establish the dose-response relation of sugammadex given as a reversal agent of rocuronium or vecuronium at 1-2 Post-Tetanic Count (PTC) during sevoflurane anesthesia for Caucasian participants

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rocuronium; Vecuronium Bromide

Criteria

Inclusion Criteria:

• Participants of American Society of Anesthesiologists (ASA) class 1 - 3;

• Participants at least 20 years but under 65 years of age;

• Caucasian participants ;

• Participants scheduled for elective surgery requiring muscle relaxation in supine position and under sevoflurane anesthesia, in need of administration of a neuromuscular blocking agent (NMBA), with an anticipated duration of about 1.5- 3 hours;

• Participants who had given written informed consent. This was obtained before the investigator or the sub-investigator performed any procedures or assessments for the screening, and after the participant was informed about the nature and purpose of the study, the study procedures, and the risks and restrictions of the study.

Exclusion criteria:

• Participants in whom a difficult intubation because of anatomical malformations was expected;

• Participants known or suspected to have neuromuscular disorders impairing neuromuscular blockade (NMB) and/or significant renal dysfunction (for example a creatinine level > 1.6 mg/dl) and/or severe hepatic dysfunction.

• Participants known or suspected to have a (family) history of malignant hyperthermia;

• Participants known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;

• Participants receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration;

• Female participants who were pregnant;

• Female participants of childbearing potential not using birth control or using only oral contraception as birth control;

• Participants who were breast-feeding;

• Participants who had already participated in CT 19.4.209B, or in another trial with sugammadex;

• Participants who had participated in another clinical trial, not preapproved by Organon, within 6 months of entering into CT 19.4.209B.